BR351 inhibits MMPs, enzymes that degrade extracellular matrix components, thus having potential therapeutic applications in cancer and chronic inflammatory diseases. It targets MMP-2, MMP-8, MMP-9, and MMP13.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.